Momat Rhino, spray 50 mcg/dose 120 doses

ATC code: R01AD09.

Pharmacological properties: Pharmacodynamics

Mometazon is a synthetic glucocorticosteroid (GCS) for topical use. It has anti-inflammatory and anti-allergic effects when used in doses that do not develop systemic effects. Inhibits the release of inflammatory mediators. Increases production of lipomodulin, which is an inhibitor of phospholipase A, resulting in reduced release of arachidonic acid and, consequently, inhibition of the synthesis of products of arachidonic acid metabolism – cyclic endoperoxides, prostaglandins. It prevents marginal accumulation of neutrophils that reduces inflammatory exudate and lymphokine production, inhibits macrophage migration, leads to decrease of infiltration and granulation processes.

It reduces inflammation due to decrease of chemotaxis substance formation (effect on “late” allergy reactions), inhibits development of immediate allergic reaction (caused by inhibition of arachidonic acid metabolites production and decrease of inflammatory mediators release from mast cells).

In studies with provocation tests with application of antigens on nasal mucosa high anti-inflammatory activity of mometasone was demonstrated both in early and in late stage of allergic reaction. This was confirmed by a decrease (compared to placebo) in the level of histamine and eosinophil activity, as well as a decrease (compared to baseline) in the number of eosinophils, neutrophils and epithelial cell adhesion proteins.

In clinical studies it was found that mometazone furoate in the form of a dosed nasal spray reduces nasal symptoms of seasonal and year-round allergic rhinitis (nasal congestion, rhinorrhea, itching and sneezing). Reduction of the severity of symptoms of seasonal allergic rhinitis was noted within 11 hours after the first administration of the drug. Maximum favorable effect was usually observed within ‑12 weeks after the beginning of the drug administration.

Therapy with mometasone preparation in form of nasal spray significantly reduced nasal congestion in patients with seasonal allergic rhinitis.‑

When administered intranasally the systemic bioavailability of mometasone furoate is <1% (with a sensitivity of 0.25 pg/mL determination method). Mometasone furoate in suspension form is very poorly absorbed in the gastrointestinal tract, and the small amount of mometasone suspension that may enter the gastrointestinal ‑tract by intranasal administration undergoes active primary metabolism before excretion with urine or bile.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Pregnancy use

Similarities